09:49 AM EST - Eupraxia Pharmaceuticals Inc. : Announced that the Company will present 4 abstracts at Digestive Disease Week Annual meeting being held May 2-5 in Chicago. Clinical data will be presented from the ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis. Eupraxia Pharmaceuticals Inc.
shares T.EPRX are trading up $0.12 at $9.75.
